Beads (1)Antibody (1)
Online (2)
Rabbit (2)
- (2)
- (1)Acridinium ester Labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
AMG-S163 | HEK293 | Anti-Mouse IgG-Acridinium ester (MALS verified) | |||||
MPC-A003 | - | Anti-Mouse IgG-coupled Magnetic Beads (recommended for MPCLIA) |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Belapectin | GR-MD-02 | Phase 3 Clinical | Galectin Therapeutics Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Squamous Cell Carcinoma of Head and Neck; Fibrosis; Hypertension, Portal; Psoriasis; Hepatic Insufficiency; Esophageal and Gastric Varices; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | The University Of Edinburgh, Lund University Foundation | Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19) | Details |
| Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Head and Neck Neoplasms; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Coronaviridae Infections; Colorectal Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Melanoma | Details |
| Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Squamous Cell Carcinoma of Head and Neck; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatic Insufficiency; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ProLectin-M | Phase 2 Clinical | BioXyTran Inc | Cytokine Release Syndrome; Coronavirus Disease 2019 (COVID-19); Influenza, Human | Details | |
| Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Venous Thrombosis; Eye Diseases; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |

BettinastraBe 30, 60325 Frankfurt am Main



